Feature | December 15, 2014

St. Joseph's Children's Hospital Implants 50th Pulmonary Valve Without Open-Heart Surgery

Facility is highest-volume Melody valve implanting center in Florida, one of the busiest in the United States

December 15, 2014 — Doctors at St. Joseph’s Children’s Hospital of Tampa implanted a Melody transcatheter pulmonary valve in a 13-year-old patient in October, marking the 50th time the hospital has given the device to a patient.

Thirteen-year-old Cyrus Yarley was born with multiple heart defects and underwent open-heart surgery at just 1 week old then again at age 8. His mother, Valorie Daniels, knew the day would come when Cyrus would need to have his pulmonary valve replaced, and had anticipated another open-heart surgery for the past five years. Use of the Melody valve, however, precluded the need for an additional incision. After inserting a catheter into a vein in the upper leg, pediatric cardiologist Jeremy Ringewald, M.D., guided the Melody valve up to Cyrus' heart and replaced his current dysfunctional pulmonary valve

The Melody valve from Medtronic replaces narrow or leaky pulmonary valve conduits in children or adults who have previously undergone congenital heart surgery. St. Joseph's Children's Hospital is the highest-volume Melody valve implanting center in Florida and one of the busiest in the United States.

"Children born with blocked or leaky heart valves usually undergo multiple open-heart surgeries before reaching adulthood to replace conduits that have worn out or that they have outgrown," said Ringewald. "This groundbreaking technology can markedly prolong the time between surgeries for many patients, with the goal of maximizing heart health and minimizing invasiveness."

According to Ringewald, the Melody valve procedure is typically performed under general anesthesia in less than four hours. Unlike open-heart surgical procedures, where the hospital stay is approximately a week, patients are usually discharged from the hospital within 24 hours. 

While Melody valve therapy cannot be used in all cases of abnormal pulmonary valve function, it can give doctors an alternative to repeated traditional open-heart procedures, offering children and adults who may not be able to tolerate another open-heart surgery hope for the future.

For more information: www.medtronic.com

Related Content

Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation
News | Heart Valve Technology | February 22, 2018
NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology | December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology | November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Overlay Init